WO2009102715A3 - Peptide therapy for ocular herpes infections - Google Patents

Peptide therapy for ocular herpes infections Download PDF

Info

Publication number
WO2009102715A3
WO2009102715A3 PCT/US2009/033672 US2009033672W WO2009102715A3 WO 2009102715 A3 WO2009102715 A3 WO 2009102715A3 US 2009033672 W US2009033672 W US 2009033672W WO 2009102715 A3 WO2009102715 A3 WO 2009102715A3
Authority
WO
WIPO (PCT)
Prior art keywords
ocular
apolipoprotein
residues
peptide
infection
Prior art date
Application number
PCT/US2009/033672
Other languages
French (fr)
Other versions
WO2009102715A2 (en
Inventor
James M. Hill
Partha S. Bhattacharjee
Donna M. Neumann
Original Assignee
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College filed Critical Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
Publication of WO2009102715A2 publication Critical patent/WO2009102715A2/en
Publication of WO2009102715A3 publication Critical patent/WO2009102715A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

New compositions and methods for treating ocular keratitis caused by infection of herpes simplex virus (HSV) have been discovered involving the topical use of a memetic peptide of Apolipoprotein E, the tandem repeat dipeptide based on residues 141 -149. Topical application of this dipeptide in an in vivo mammalian model system (both mice and rabbit) significantly reduced the damage to the cornea, including a decrease in opacity, in neovascularization, in immune response, and in ocular viral titers. In addition, this compound can be used in combination with other compounds in decreasing the effects of an ocular herpes infection, including the 17 amino acid peptide of Apolipoprotein E residues 133-149 (SEQ ID NO: 2), trifluorothymidine, acyclovir, and steroidal and non-steroidal anti-inflammatory agents.
PCT/US2009/033672 2008-02-11 2009-02-10 Peptide therapy for ocular herpes infections WO2009102715A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2757908P 2008-02-11 2008-02-11
US61/027,579 2008-02-11

Publications (2)

Publication Number Publication Date
WO2009102715A2 WO2009102715A2 (en) 2009-08-20
WO2009102715A3 true WO2009102715A3 (en) 2009-10-08

Family

ID=40957456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/033672 WO2009102715A2 (en) 2008-02-11 2009-02-10 Peptide therapy for ocular herpes infections

Country Status (1)

Country Link
WO (1) WO2009102715A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20095592A0 (en) * 2009-05-28 2009-05-28 Matti Waris Differentiation of picornaviruses, nucleic acids therefor, use of same and bioassay procedures using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005895A1 (en) * 1995-08-07 1997-02-20 Schering Corporation Treatment of ocular inflammatory conditions with interleukin-10
US6369101B1 (en) * 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US20070117746A1 (en) * 2003-12-17 2007-05-24 A12 Limited Treatment of viral infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005895A1 (en) * 1995-08-07 1997-02-20 Schering Corporation Treatment of ocular inflammatory conditions with interleukin-10
US6369101B1 (en) * 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US20070117746A1 (en) * 2003-12-17 2007-05-24 A12 Limited Treatment of viral infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DOBSON, C.B. ET AL.: "The receptor-binding region of human apolipoprotein E has direct anti- infective activity", J INFECT DIS., vol. 193, no. 3, 2006, pages 442 - 450 *

Also Published As

Publication number Publication date
WO2009102715A2 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
WO2011106106A3 (en) Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
NZ591130A (en) Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
CY1119765T1 (en) HISTORICAL-CONNECTED ISOSOMATIDA VIRUS WITH EXCHANGE EXCHANGE AND METHODS OF USE THEREOF
MX2009001200A (en) Antiviral use of cationic surfactant.
NZ590050A (en) Fgf21 mutants and uses thereof
JP2016128513A5 (en)
US8748565B2 (en) Pharmacologically active antiviral peptides and methods of their use
EP2206512A2 (en) Increase of interferon-beta for anti-virus therapy for respiratory diseases
NZ601868A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2007048086A3 (en) Canine influenza virus and related compositions and methods of use
WO2010051541A3 (en) Compositions containing delta-9-thc-amino acid esters and process of preparation
MA27581A1 (en) VIRAL PSEUDO-PARTICLE VACCINE OF PAPILLOMAVIRUS PROTEIN L1 16 AND 18
EP2532366A4 (en) Pharmaceutical composition for treating and/or preventing cancer
WO2009076173A3 (en) Fluorinated tripeptide hcv serine protease inhibitors
EP1801206A4 (en) Method for producing l-arginine, l-ornithine or l-citrulline
WO2009076166A3 (en) Oximyl hcv serine protease inhibitors
WO2008019213A3 (en) Use of extracts for the treatment of viral disorders
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
JP2015510759A5 (en)
RU2005126236A (en) FUSION PROTEIN FOR SUPPRESSING CERVICAL CANCER
WO2010151495A3 (en) Materials and methods for treating and preventing viral infections
WO2008111532A1 (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
WO2008063865A3 (en) Biphosphonate inhalant formulations and methods for using the same
JP2014504297A5 (en)
WO2009102715A3 (en) Peptide therapy for ocular herpes infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09709672

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09709672

Country of ref document: EP

Kind code of ref document: A2